Vir Biotechnology (VIR) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free VIR Stock Alerts $10.08 +0.31 (+3.17%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 7:21 PM | prnewswire.comBrii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesMay 10, 2024 | americanbankingnews.comVir Biotechnology, Inc. to Post FY2024 Earnings of ($3.13) Per Share, HC Wainwright Forecasts (NASDAQ:VIR)May 9, 2024 | marketbeat.comResearch Analysts Offer Predictions for Vir Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:VIR)Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will postMay 9, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)May 8, 2024 | finance.yahoo.comAnalysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) EstimatesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical PipelineMay 7, 2024 | markets.businessinsider.comDeep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)May 7, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday.May 5, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) PT Raised to $12.00May 5, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Stock Rating Reaffirmed by Needham & Company LLCMay 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Announces Quarterly Earnings ResultsVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Thursday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.06) earnings per share.May 3, 2024 | marketbeat.comVir Biotechnology's (VIR) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday.May 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $12.00JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a "neutral" rating in a research report on Friday.May 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Strong EarningsVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Better-Than-Expected EarningsMay 3, 2024 | seekingalpha.comVir Biotechnology Provides Some Hope For Its Beleaguered ShareholdersMay 3, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comQ1 2024 Vir Biotechnology Inc Earnings CallMay 2, 2024 | investorplace.comVIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024May 2, 2024 | msn.comVir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67MMay 2, 2024 | businesswire.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comVir Biotechnology earnings preview: what Wall Street is expectingApril 30, 2024 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024April 28, 2024 | finance.yahoo.comWith 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backingApril 26, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 7.6% Higher Vir Biotechnology (NASDAQ:VIR) Trading Up 7.6%April 26, 2024 | msn.comSouthern policies help level up investment from East AsiaApril 25, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low at $7.65Vir Biotechnology (NASDAQ:VIR) Sets New 12-Month Low at $7.65April 20, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Purchases 155,196 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 268.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 212,902 shares of the company's stock after purchasing an additionaApril 18, 2024 | finance.yahoo.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsApril 18, 2024 | businesswire.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.April 16, 2024 | morningstar.comVir Biotechnology IncApril 11, 2024 | finance.yahoo.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 11, 2024 | businesswire.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 9, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendatioApril 5, 2024 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells 72,995 Shares of StockApril 5, 2024 | marketbeat.comVanguard Group Inc. Boosts Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Vanguard Group Inc. increased its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 9.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,200,666 shares of the company'sApril 4, 2024 | finance.yahoo.comVir Biotechnology Inc CEO Backer De Sells 72,995 SharesApril 4, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $690,532.70 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 72,995 shares of the company's stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now directly owns 678,457 shares in the company, valued at approximately $6,418,203.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.April 3, 2024 | insidertrades.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $27,245.55 in StockApril 3, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Ann M. Hanly Sells 2,711 SharesVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Ann M. Hanly sold 2,711 shares of the company's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $10.05, for a total value of $27,245.55. Following the completion of the sale, the executive vice president now owns 132,069 shares in the company, valued at $1,327,293.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.March 29, 2024 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Sells 6,008 Shares of StockMarch 28, 2024 | marketbeat.comSung Lee Sells 6,008 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CFO Sung Lee sold 6,008 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $9.89, for a total value of $59,419.12. Following the completion of the transaction, the chief financial officer now directly owns 100,492 shares in the company, valued at approximately $993,865.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 21, 2024 | finance.yahoo.comBillionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ PortfolioMarch 19, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 4.8%Vir Biotechnology (NASDAQ:VIR) Shares Down 4.8%March 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 18, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday.March 17, 2024 | marketbeat.comHudson Bay Capital Management LP Buys 197,500 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Hudson Bay Capital Management LP raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 1,975.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,March 16, 2024 | ca.finance.yahoo.comVIR Jul 2024 17.500 call Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Former Wingman Bets Big on AI (Ad)One of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information. Get the full story here. VIR Media Mentions By Week VIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.730.56▲Average Medical News Sentiment VIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼94▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FDMT News CGEM News TARS News SRRK News NMRA News ADMA News BCRX News AUTL News MESO News IMTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
